Electrophysiologic Complications in Cancer Patients

Dae Hyun Lee; Sanjay Chandrashekhar; Michael G. Fradley

doi:10.14797/mdcj-15-4-282

Electrophysiologic Complications in Cancer Patients

Methodist DeBakey Cardiovascular Journal

Volume 15 (2019): Issue 4

By: Dae Hyun Lee, Sanjay Chandrashekhar and Michael G. Fradley

Open Access

|Oct 2019

Abstract

In recent years, dramatic advances in both cancer diagnosis and treatment have led to significantly increased survival rates. As such, cardiovascular toxicities due to oncologic treatments are more frequently identified. Although heart failure and cardiomyopathy have historically been the cardiotoxicities most associated with cancer therapeutics, it is now recognized that all components of the cardiovascular system can be affected. In this review, we discuss electrophysiologic complications of cancer treatments, including atrial and ventricular tachyarrhythmias as well as bradyarrhythmias, and recommend a multidisciplinary approach with both cardiologists and oncologists to provide safe and effective care to these patients.

References

Siegel RL Miller KD Jemal A Cancer statistics, 2018 CA Cancer J Clin 2018 Jan 68 1 7 30
Search in Google Scholar Back to article
Buza V Rajagopalan B Curtis AB Cancer Treatment-Induced Arrhythmias: Focus on Chemotherapy and Targeted Therapies Circ Arrhythm Electrophysiol 2017 Aug 10 8
Search in Google Scholar Back to article
Mahmood SS Fradley MG Cohen JV Myocarditis in Patients Treated With Immune Checkpoint Inhibitors J Am Coll Cardiol 2018 Apr 24 71 16 1755 64
Search in Google Scholar Back to article
January CT Wann LS Calkins H 2019 AHA/ACC/HRS Focused Update of the 2014 AHA/ACC/HRS Guideline for the Management of Patients With Atrial Fibrillation: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Rhythm Society J Am Coll Cardiol 2019 Jul 9 74 1 104 32
Search in Google Scholar Back to article
Tamargo J Caballero R Delpón E Cancer chemotherapy and cardiac arrhythmias: a review Drug Saf 2015 Feb 38 2 129 52
Search in Google Scholar Back to article
Feliz V Saiyad S Ramarao SM Khan H Leonelli F Guglin M Melphalan-induced supraventricular tachycardia: incidence and risk factors Clin Cardiol 2011 Jun 34 6 356 9
Search in Google Scholar Back to article
Kilickap S Barista I Akgul E Aytemir K Aksoy S Tekuzman G Early and late arrhythmogenic effects of doxorubicin South Med J 2007 Mar 100 3 262 5
Search in Google Scholar Back to article
Mazur M Wang F Hodge DO Burden of Cardiac Arrhythmias in Patients With Anthracycline-Related Cardiomyopathy JACC Clin Electrophysiol 2017 Feb 3 2 139 50
Search in Google Scholar Back to article
Fradley MG Viganego F Kip K Rates and risk of arrhythmias in cancer survivors with chemotherapy-induced cardiomyopathy compared with patients with other cardiomyopathies Open Heart 2017 Dec 17 4 2 e000701
Search in Google Scholar Back to article
Zellos L Richards WG Capalbo L A phase I study of extrapleural pneumonectomy and intracavitary intraoperative hyperthermic cisplatin with amifostine cytoprotection for malignant pleural mesothelioma J Thorac Cardiovasc Surg 2009 Feb 137 2 453 8
Search in Google Scholar Back to article
Petrini I Lencioni M Ricasoli M Phase II trial of sorafenib in combination with 5-fluorouracil infusion in advanced hepatocellular carcinoma Cancer Chemother Pharmacol 2012 Mar 69 3 773 80
Search in Google Scholar Back to article
Byrd JC Brown JR O'Brien S RESONATE Investigators Ibrutinib versus ofatumumab in previously treated chronic lymphoid leukemia N Engl J Med 2014 Jul 17 371 3 213 23
Search in Google Scholar Back to article
Fradley MG Gliksman M Emole J Rates and Risk of Atrial Arrhythmias in Patients Treated With Ibrutinib Compared With Cytotoxic Chemotherapy Am J Cardiol 2019 Aug 15 124 4 539 544
Search in Google Scholar Back to article
Leong DP Caron F Hillis C The risk of atrial fibrillation with ibrutinib use: a systematic review and meta-analysis Blood 2016 Jul 7 128 1 138 40
Search in Google Scholar Back to article
Wiczer TE Levine LB Brumbaugh J Cumulative incidence, risk factors, and management of atrial fibrillation in patients receiving ibrutinib Blood Adv 2017 Sep 8 1 20 1739 48
Search in Google Scholar Back to article
Mato AR Clasen S Pickens P Left atrial abnormality (LAA) as a predictor of ibrutinib-associated atrial fibrillation in patients with chronic lymphocytic leukemia Cancer Biol Ther 2018 Jan 2 19 1 1 2
Search in Google Scholar Back to article
McMullen JR Boey EJ Ooi JY Seymour JF Keating MJ Tam CS Ibrutinib increases the risk of atrial fibrillation, potentially through inhibition of cardiac PI3K-Akt signaling Blood 2014 Dec 11 124 25 3829 30
Search in Google Scholar Back to article
Lee DH Fradley MG Cardiovascular Complications of Multiple Myeloma Treatment: Evaluation, Management, and Prevention Curr Treat Options Cardiovasc Med 2018 Mar 6 20 3 19
Search in Google Scholar Back to article
Heinzerling L Ott PA Hodi FS Cardiotoxicity associated with CTLA4 and PD1 blocking immunotherapy J Immunother Cancer 2016 Aug 16 4 50
Search in Google Scholar Back to article
Alvi RM Mahmood S Hassan MZO The cardiovascular effects of chimeric antigen receptor T-cells J Am Coll Cardiol 2019 Mar 73 9 Suppl 1 722
Search in Google Scholar Back to article
January CT Wann LS Alpert JS American College of Cardiology/American Heart Association Task Force on Practice Guidelines 2014 AHA/ACC/HRS guideline for the management of patients with atrial fibrillation: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the Heart Rhythm Society J Am Coll Cardiol 2014 Dec 2 64 21 e1 76
Search in Google Scholar Back to article
D'Souza M Carlson N Fosbøl E CHA2DS2-VASc score and risk of thromboembolism and bleeding in patients with atrial fibrillation and recent cancer Eur J Prev Cardiol 2018 Apr 25 6 651 8
Search in Google Scholar Back to article
Hu WS Lin CL Impact of atrial fibrillation on the development of ischemic stroke among cancer patients classified by CHA2DS2-VASc score-a nationwide cohort study Oncotarget 2018 Jan 10 9 7 7623 30
Search in Google Scholar Back to article
Lip GY Frison L Halperin JL Lane DA Comparative validation of a novel risk score for predicting bleeding risk in anticoagulated patients with atrial fibrillation: the HAS-BLED (Hypertension, Abnormal Renal/Liver Function, Stroke, Bleeding History or Predisposition, Labile INR, Elderly, Drugs/Alcohol Concomitantly) score J Am Coll Cardiol 2011 Jan 11 57 2 173 80
Search in Google Scholar Back to article
Fradley M Ellenberg K Swanson J Patterns of anticoagulation use in cancer patients with atrial fibrillation and/or atrial flutter J Am Coll Cardiol 2019 Mar 73 9 Suppl 1 504
Search in Google Scholar Back to article
Shah S Norby FL Datta YH Comparative effectiveness of direct oral anticoagulants and warfarin in patients with cancer and atrial fibrillation Blood Adv 2018 Feb 13 2 3 200 9
Search in Google Scholar Back to article
Wang ML Rule S Martin P Targeting BTK with ibrutinib in relapsed or refractory mantle-cell lymphoma N Engl J Med 2013 Aug 8 369 6 507 16
Search in Google Scholar Back to article
Ganatra S Sharma A Shah S Ibrutinib-Associated Atrial Fibrillation JACC Clin Electrophysiol 2018 Dec 4 12 1491 1500
Search in Google Scholar Back to article
Fradley MG Moslehi J QT Prolongation and Oncology Drug Development Card Electrophysiol Clin 2015 Jun 7 2 341 55
Search in Google Scholar Back to article
Naing A Veasey-Rodrigues H Hong DS Electrocardiograms (ECGs) in phase I anticancer drug development: the MD Anderson Cancer Center experience with 8518 ECGs Ann Oncol 2012 Nov 23 11 2960 3
Search in Google Scholar Back to article
Lenihan DJ Kowey PR Overview and management of cardiac adverse events associated with tyrosine kinase inhibitors Oncologist 2013 18 8 900 8
Search in Google Scholar Back to article
Roboz GJ Ritchie EK Carlin RF Prevalence, management, and clinical consequences of QT interval prolongation during treatment with arsenic tri-oxide J Clin Oncol 2014 Nov 20 32 33 3723 8
Search in Google Scholar Back to article
US Food and Drug Administration [Internet] Silver Spring, MD US Food and Drug Administration 2019 Warning: Differentiation syndrome and cardiac conduction abnormalities; 2019 [cited 2019 Jul 22]. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/021248s015lbl.pdf
Search in Google Scholar Back to article
National Comprehensive Cancer Network [Internet] Plymouth Meeting, PA National Comprehensive Cancer Network 2019 Cancer-associated venous thromboembolic disease; 2018 Feb [cited 2019 Jul 22]. Available from: https://www.nccn.org/professionals/physician_gls/pdf/vte.pdf
Search in Google Scholar Back to article
Infante JR Cassier PA Gerecitano JF A Phase I Study of the Cyclin-Dependent Kinase 4/6 Inhibitor Ribociclib (LEE011) in Patients with Advanced Solid Tumors and Lymphomas Clin Cancer Res 2016 Dec 1 22 23 5696 705
Search in Google Scholar Back to article
Armanious MA Mishra S Fradley MG Electrophysiologic Toxicity of Chemo-radiation Curr Oncol Rep 2018 Apr 11 20 6 45
Search in Google Scholar Back to article
Abdel-Rahman O Toxicity patterns associated with chemotherapy/immune checkpoint inhibitor combinations: a meta-analysis Immunotherapy 2019 Apr 11 6 543 54
Search in Google Scholar Back to article
Porta-Sánchez A Gilbert C Spears D Incidence, Diagnosis, and Management of QT Prolongation Induced by Cancer Therapies: A Systematic Review J Am Heart Assoc 2017 Dec 7 6 12
Search in Google Scholar Back to article
Fradley MG Pinilla-Ibarz J Arrhythmic complications of tyrosine kinase inhibitors Future Cardiol 2015 Jul 11 4 395 9
Search in Google Scholar Back to article
Kim TD le Coutre P Schwarz M Clinical cardiac safety profile of nilotinib Haematologica 2012 Jun 97 6 883 9
Search in Google Scholar Back to article
Zang J Wu S Tang L Incidence and risk of QTc interval prolongation among cancer patients treated with vandetanib: a systematic review and meta-analysis PLoS One 2012 7 2 e30353
Search in Google Scholar Back to article
Porta-Sánchez A Gilbert C Spears D Incidence, Diagnosis, and Management of QT Prolongation Induced by Cancer Therapies: A Systematic Review J Am Heart Assoc 2017 Dec 7 6 12
Search in Google Scholar Back to article
Guha A Derbala MH Zhao Q Ventricular Arrhythmias Following Ibrutinib Initiation for Lymphoid Malignancies J Am Coll Cardiol 2018 Aug 7 72 6 697 8
Search in Google Scholar Back to article
Ou SH Tang Y Polli A Wilner KD Schnell P Factors associated with sinus bradycardia during crizotinib treatment: a retrospective analysis of two large-scale multinational trials (PROFILE 1005 and 1007) Cancer Med 2016 Apr 5 4 617 22
Search in Google Scholar Back to article
Zhang Z Huang TQ Nepliouev I Crizotinib Inhibits Hyperpolarization-activated Cyclic Nucleotide-Gated Channel 4 Activity Cardiooncology 2017 3
Search in Google Scholar Back to article
McGuire WP Rowinsky EK Rosenshein NB Taxol: a unique antineoplastic agent with significant activity in advanced ovarian epithelial neoplasms Ann Intern Med 1989 Aug 15 111 4 273 9
Search in Google Scholar Back to article
Arbuck SG Strauss H Rowinsky E A reassessment of cardiac toxicity associated with Taxol J Natl Cancer Inst Monogr 1993 15 117 30
Search in Google Scholar Back to article
Johnson DB Balko JM Compton ML Fulminant Myocarditis with Combination Immune Checkpoint Blockade N Engl J Med 2016 Nov 3 375 18 1749 55
Search in Google Scholar Back to article
Zaremba T Jakobsen AR Søgaard M Risk of device malfunction in cancer patients with implantable cardiac device undergoing radiotherapy: a population-based cohort study Pacing Clin Electrophysiol 2015 Mar 38 3 343 56
Search in Google Scholar Back to article
Viganego F Singh R Fradley MG Arrhythmias and Other Electrophysiology Issues in Cancer Patients Receiving Chemotherapy or Radiation Curr Cardiol Rep 2016 Jun 18 6 52
Search in Google Scholar Back to article
Grant JD Jensen GL Tang C Radiotherapy-Induced Malfunction in Contemporary Cardiovascular Implantable Electronic Devices: Clinical Incidence and Predictors JAMA Oncol 2015 Aug 1 5 624 32
Search in Google Scholar Back to article
Brambatti M Mathew R Strang B Management of patients with implantable cardioverter-defibrillators and pacemakers who require radiation therapy Heart Rhythm 2015 Oct 12 10 2148 54
Search in Google Scholar Back to article

Articles in this issue

DOI: https://doi.org/10.14797/mdcj-15-4-282 | Journal eISSN: 1947-6108

Journal RSS Feed

Language: English

Page range: 282 - 288

Published on: Oct 1, 2019

Published by: Houston Methodist DeBakey Heart & Vascular Center

In partnership with: Paradigm Publishing Services

Keywords:

cardio-oncology,

atrial arrhythmias,

ventricular arrhythmias,

bradyarrhythmias,

cardiotoxicity

© 2019 Dae Hyun Lee, Sanjay Chandrashekhar, Michael G. Fradley, published by Houston Methodist DeBakey Heart & Vascular Center
This work is licensed under the Creative Commons Attribution-NonCommercial 4.0 License.

Volume 15 (2019): Issue 4